Wanted: Drugs to Fight Bioterror

Wanted: Drugs to Fight Bioterror “Amid new warnings about a possible summer of terror, the U.S. government is preparing to spend billons to coax pharmaceutical companies to develop drugs to fend off a biological or chemical attack. But experts say the infusion of cash may be little more than a good start.”


Eco-Terror Cited as Top Threat

Eco-Terror Cited as Top Threat Law enforcement officials warn that biotechnology firms, particularly those that conduct research on animals, must take greater precautions against attacks by extremist groups.


The Drug Research War

The Drug Research War “Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which is the heart of pharmaceutical and biotech companies, is growing at a yearly clip of 15% to 20%. Right now the lion’s share of the work has gone to U.S. companies that focus on drug […]


Will U.S. try to circumvent drug firms patent?

Will U.S. try to circumvent drug firms patent? : The furor over Abbott Laboratories’ 400 percent price increase last December of the AIDS drug Norvir has resulted in an unprecedented meeting at the National Institutes of Health to consider circumventing the drug giant’s patent.


Another gene genie out of the bottle

Another gene genie out of the bottle The European Commission has lifted a five-year moratorium on genetically modified produce, by allowing the sale in Europe of one type of modified corn. But the battle by producers of such crops to win governments� and consumers� acceptance is far from over


Could patients glean stock tips?: Drug trial participants may be insider trading.

Could patients glean stock tips?: Drug trial participants may be insider trading. “Patients in clinical trials might be using information about the drug they are taking to trade illegally in pharmaceutical stocks, warns a group of doctors and bioethicists. But they have no idea how prevalent the problem might be.”


Financial Snapshot For March 2004: Looking Good

Financial Snapshot For March 2004: Looking Good “It’s been a rocky first quarter for the biotech stocks � and for the markets in general. Yet, despite investors’ nervousness � about issues as diverse as the terrorist train bombing in Madrid and the departure of Mark McClellan from the FDA � the biotech sector managed to […]


Do NOT follow this link or you will be banned from the site!